bioMérieux (BIM) Q3 2025 TU earnings summary

Executive summary

• Q3 2025 organic sales grew 3%, reaching nearly EUR 950 million, with 7.6% growth excluding China and respiratory panel; YTD organic sales up 7.3% to €2,992m, driven by key product lines and regions.

• Spotfire installations expanded by over 900 in Q3, with the install base up 160% YoY to 5,500; Spotfire sales more than doubled YTD (+114%).

• BioFire non-respiratory panels grew 9% organically in Q3 and 10% YTD, with strong EMEA and Latin America performance.

• Profitability remains solid over nine months, supported by GOSSIMPLE initiatives in automation, headcount, purchasing, and supply chain.

• Q3 growth was impacted by declines in China and BioFire respiratory panels.

Financial highlights

• Q3 organic sales growth was 3%, with reported sales down 2% due to a EUR 51 million negative FX impact; YTD consolidated sales were €2,992m, up 4.2% as reported and 7.3% organically.

• Spotfire sales in Q3 were EUR 32 million (+66% organic), with a 2025 target of EUR 170 million.

• BioFire respiratory panel sales declined 8% in Q3, but rose 6% organically over nine months.

• Immunoassay sales declined, driven by a 17% drop in procalcitonin and continued weakness in China.

• Currency effects negatively impacted sales by €85m over nine months, mainly due to euro appreciation.

Outlook and guidance

• Full-year 2025 sales growth guidance revised to 5.5-6.5% at constant exchange rates, down from 6-7.5%.

• Spotfire 2025 sales target revised to EUR 170 million (~90% organic growth), with 2028 target of EUR 450 million reaffirmed.

• CBIT/CEBIT growth guidance for 2025 confirmed at 12-18% at constant exchange rates, with a -€30m currency effect expected.

• Tariffs expected to have a EUR 35 million gross impact in 2026, with EUR 5-10 million net impact in 2025; mitigation actions underway.